[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112017004136A2 - sondas para imageamento de proteína de huntingtina - Google Patents

sondas para imageamento de proteína de huntingtina

Info

Publication number
BR112017004136A2
BR112017004136A2 BR112017004136A BR112017004136A BR112017004136A2 BR 112017004136 A2 BR112017004136 A2 BR 112017004136A2 BR 112017004136 A BR112017004136 A BR 112017004136A BR 112017004136 A BR112017004136 A BR 112017004136A BR 112017004136 A2 BR112017004136 A2 BR 112017004136A2
Authority
BR
Brazil
Prior art keywords
imaging probes
huntingtin protein
protein imaging
huntingtin
probes
Prior art date
Application number
BR112017004136A
Other languages
English (en)
Other versions
BR112017004136B1 (pt
Inventor
Dominguez Celia
John Brown Christopher
CLARK-FREW Daniel
Wityak John
Bard Jonathan
HAYES Sarah
Martin KRÜLLE Thomas
Original Assignee
Chdi Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chdi Foundation Inc filed Critical Chdi Foundation Inc
Publication of BR112017004136A2 publication Critical patent/BR112017004136A2/pt
Publication of BR112017004136B1 publication Critical patent/BR112017004136B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

trata-se de agentes de imagemamento que compreende um composto de fórmula i, ou um sal farmaceuticamente aceitável do mesmo, e métodos de seu uso.
BR112017004136-7A 2014-08-29 2015-08-28 Agente de imagemamento, seu uso e compostos BR112017004136B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462043644P 2014-08-29 2014-08-29
US62/043,644 2014-08-29
PCT/US2015/047396 WO2016033436A1 (en) 2014-08-29 2015-08-28 Probes for imaging huntingtin protein

Publications (2)

Publication Number Publication Date
BR112017004136A2 true BR112017004136A2 (pt) 2017-12-12
BR112017004136B1 BR112017004136B1 (pt) 2022-05-03

Family

ID=55400644

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017004136-7A BR112017004136B1 (pt) 2014-08-29 2015-08-28 Agente de imagemamento, seu uso e compostos

Country Status (20)

Country Link
US (2) US11071793B2 (pt)
EP (1) EP3186241B1 (pt)
JP (3) JP2017527559A (pt)
KR (1) KR102410760B1 (pt)
CN (2) CN118005611A (pt)
AU (1) AU2015308765B2 (pt)
BR (1) BR112017004136B1 (pt)
CA (1) CA2959531C (pt)
DK (1) DK3186241T3 (pt)
EA (1) EA037275B1 (pt)
ES (1) ES2841746T3 (pt)
HR (1) HRP20202032T1 (pt)
HU (1) HUE052892T2 (pt)
IL (1) IL250805B (pt)
MX (2) MX2017002704A (pt)
PL (1) PL3186241T3 (pt)
PT (1) PT3186241T (pt)
SG (1) SG11201701578YA (pt)
SI (1) SI3186241T1 (pt)
WO (1) WO2016033436A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2841746T3 (es) 2014-08-29 2021-07-09 Chdi Foundation Inc Sondas para la imagen de la proteína de Huntington
ES2898965T3 (es) 2014-08-29 2022-03-09 Chdi Foundation Inc Sondas de formación de imágenes de la proteína Huntingtina
ES2905095T3 (es) 2014-08-29 2022-04-07 Chdi Foundation Inc Sondas para obtención de imagen de la proteína huntingtina
CA2959505A1 (en) 2014-08-29 2016-03-03 Chdi Foundation, Inc. Probes for imaging huntingtin protein
PT3340796T (pt) 2015-08-28 2021-07-28 Chdi Foundation Inc Sondas para imagens da proteína huntingtina
CA3041033A1 (en) 2016-09-12 2018-03-15 Numerate, Inc. Monocyclic compounds useful as gpr120 modulators
CA3041038A1 (en) * 2016-09-12 2018-03-15 Numerate, Inc. Bicyclic compounds useful as gpr120 modulators
JP2022521431A (ja) 2019-02-25 2022-04-07 シーエイチディーアイ ファウンデーション，インコーポレーテッド 変異型ハンチンチンタンパク質を標的とするための化合物及びその使用
JP2023507185A (ja) * 2019-12-18 2023-02-21 シーエイチディーアイ ファウンデーション，インコーポレーテッド ハンチンチンタンパク質をイメージングするための化合物及びプローブ
US20220339302A1 (en) * 2021-04-08 2022-10-27 Chdi Foundation, Inc. Isoindolinone compounds and imaging agents for imaging huntingtin protein

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726197A (en) * 1992-11-02 1998-03-10 Syntex (U.S.A.) Inc. Isoindolinyl derivatives
ES2223531T3 (es) * 1999-06-10 2005-03-01 Warner-Lambert Company Llc Metodo de inhibir la agregacion de proteinas amiloides y de formacion de imagenes de depositos amiloides usando derivados de isoindolina.
EP1481679B1 (en) * 2002-03-01 2010-08-25 Takeda Pharmaceutical Company Limited Antidepressant
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7320992B2 (en) * 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
US8110681B2 (en) * 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
US20100267712A1 (en) * 2007-09-27 2010-10-21 The United States of America, as represented by the Secretary, Department of Health and Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
WO2009072581A1 (ja) * 2007-12-05 2009-06-11 Aska Pharmaceutical Co., Ltd. ラクタム化合物又はその塩及びｐｐａｒ活性化剤
WO2010104324A2 (ko) * 2009-03-10 2010-09-16 한국과학기술연구원 베타-아밀로이드 집적체 및 피브릴에 우수한 결합 친화도를 가지는 할로겐화 이소인돌론 화합물, 및 이의 제조 방법 및 용도
MX360323B (es) * 2012-04-25 2018-10-29 Raqualia Pharma Inc Derivados de pirrolopiridinona como bloqueadores de ttx-s.
WO2015054317A1 (en) * 2013-10-07 2015-04-16 Kadmon Corporation, Llc Rho kinase inhibitors
ES2841746T3 (es) 2014-08-29 2021-07-09 Chdi Foundation Inc Sondas para la imagen de la proteína de Huntington
ES2905095T3 (es) 2014-08-29 2022-04-07 Chdi Foundation Inc Sondas para obtención de imagen de la proteína huntingtina
CA2959505A1 (en) 2014-08-29 2016-03-03 Chdi Foundation, Inc. Probes for imaging huntingtin protein
ES2898965T3 (es) 2014-08-29 2022-03-09 Chdi Foundation Inc Sondas de formación de imágenes de la proteína Huntingtina
PT3340796T (pt) 2015-08-28 2021-07-28 Chdi Foundation Inc Sondas para imagens da proteína huntingtina

Also Published As

Publication number Publication date
IL250805A0 (en) 2017-04-30
CA2959531C (en) 2023-01-10
DK3186241T3 (da) 2021-01-11
US11071793B2 (en) 2021-07-27
KR20170047348A (ko) 2017-05-04
JP2021088584A (ja) 2021-06-10
JP2017527559A (ja) 2017-09-21
EP3186241A1 (en) 2017-07-05
MX2021005891A (es) 2021-06-23
MX2017002704A (es) 2017-10-23
SG11201701578YA (en) 2017-03-30
US20170281804A1 (en) 2017-10-05
PL3186241T3 (pl) 2021-05-17
IL250805B (en) 2020-08-31
HUE052892T2 (hu) 2021-05-28
CA2959531A1 (en) 2016-03-03
JP7042940B2 (ja) 2022-03-28
ES2841746T3 (es) 2021-07-09
AU2015308765B2 (en) 2020-06-04
CN107074817A (zh) 2017-08-18
EP3186241A4 (en) 2018-04-18
BR112017004136B1 (pt) 2022-05-03
EA037275B1 (ru) 2021-03-03
JP2020079272A (ja) 2020-05-28
AU2015308765A1 (en) 2017-03-23
CN118005611A (zh) 2024-05-10
US12036291B2 (en) 2024-07-16
KR102410760B1 (ko) 2022-06-20
EA201790432A1 (ru) 2017-09-29
US20210379211A1 (en) 2021-12-09
PT3186241T (pt) 2021-01-08
EP3186241B1 (en) 2020-10-07
HRP20202032T1 (hr) 2021-02-19
CN107074817B (zh) 2023-12-15
JP6843282B2 (ja) 2021-03-17
SI3186241T1 (sl) 2021-03-31
WO2016033436A1 (en) 2016-03-03

Similar Documents

Publication Publication Date Title
BR112017004141A2 (pt) ?sondas para imageamento de proteína de huntingtina?
BR112017004136A2 (pt) sondas para imageamento de proteína de huntingtina
BR112017004140A2 (pt) sondas para imageamento de proteína de huntingtina
CY1123633T1 (el) Ετεροκυκλικες ενωσεις και οι χρησεις αυτων
BR112017004134A2 (pt) ?sondas para imageamento de proteína de huntingtina?
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
UY37036A (es) Compuestos inhibidores de la quinasa de unión a tank
BR112018003331A2 (pt) sondas para imagear proteína huntingtina
BR112016015706A2 (pt) composto, uso do mesmo e composição farmacêutica
CR20170230A (es) Anticuerpos anti-cd79b y métodos de uso
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
BR112016027722A2 (pt) compostos contendo grupo autoimulativo e seu uso
DOP2017000178A (es) Inhibidores selectivos de bace1
CR20160362A (es) Anticuerpos anti-jagged1 y metodos de uso
BR112017011316A2 (pt) derivados heterocíclicos e uso destes
BR112016017620A2 (pt) Composto esteroidal para uso no tratamento da encefalopatia hepática
BR112017002675A2 (pt) métodos para aperfeiçoar desempenho miocárdico em pacientes de fontan com o uso de composições de udenafila
AR112602A1 (es) ANTICUERPOS ANTI-TrkB
BR112017009854A2 (pt) composto, uso de um composto, e, método para tratamento de leucemia.
BR112016021620A2 (pt) compostos e seus métodos de uso
BR112018005299A2 (pt) 1,1-difeniletilenos substituídos com alquenilfenoxi, processos para sua preparação e seu uso
BR112017026807A2 (pt) agentes solubilizantes para compostos ativos funcionais
ITUA20161994A1 (it) Uso degli inibitori ddx3 come agenti anti-iperproliferativi
BR112017008811A2 (pt) métodos para o tratamento de distúrbios renais
BR112017006916A2 (pt) uso de cantaxantina para galinhas poedeiras.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 11.1 NA RPI NO 2493 DE 16/10/2018 POR TER SIDO INDEVIDA.

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B15V Prolongation of time limit allowed

Free format text: DE ACORDO COM COMUNICADO PUBLICADO NA RPI 2487 DE 04/09/2018, COMUNICADO PUBLICADO NA RPI 2488 DE 11/09/2018 E RESOLUCAO INPI/PR NO 225/2018 FICAM DEVOLVIDOS ATE 14/09/2019 OS PRAZOS VENCIDOS NAS DATAS DIVULGADOS DENTRO DOS COMUNICADOS.

B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 11.1 NA RPI NO 2495 DE 30/10/2018 POR TER SIDO INDEVIDA.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/08/2015, OBSERVADAS AS CONDICOES LEGAIS.